Maiquan Wang, Liwei Peng, Yunfeng Li
Dept. of Stomatology, The People's Hospital of Zhengzhou University, Zhengzhou 450003, China.
State Key Laboratory of Oral Diseases, Dept. of Orthognathic and Temporomandibular Joint Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Hua Xi Kou Qiang Yi Xue Za Zhi. 2016 Aug 1;34(4):332-335. doi: 10.7518/hxkq.2016.04.002.
This study investigated the effects of systemic administration of oxytocin (OT) in osteoporotic rats on implant osseointegration.
Twenty rats were randomly assigned to the control and experimental groups. Initially, the rats underwent bilateral ovariectomy. After 12 weeks, an osteoporosis model was established. Each rat received an implant at the distal and middle femoral metaphysis. Simultaneously, systemic administration was conducted with one group receiving subcutaneous injection of OT (1 mg·kg⁻¹ per day), whereas the other group received placebo injection. After treatment for 4 weeks, another surgery was conducted to remove the thigh bones from the rats containing the implants for an eight-week observation. With the employment of micro-CT, histological observation and push-out test, osseointegration was evaluated. While the rats received thigh-bone removal surgery, another surgery was conducted to remove the tibia metaphysis from the rats of both groups to perform histological observation and micro-CT inspection.
The trabecular bone of tibial samples was intensive and formed woven mesh structure in the experimental group compared with the control group. In the experimental group, the relative bone volume/tissue volume surrounding the implant, the bone contact ratio, and the maximum push-out force of the implant were 0.35%±0.06%, 67.25%±9.06%, and (70.32±10.91) N, respectively, the corresponding values were 0.11%±0.02%, 43.25%±7.01% and (21.65±4.36) N in the control group, and the experimental group increased significantly compared with the control group (P<0.05).
Systemic administration of OT cannot only antagonize the negative effects of osteoporosis but can also promote implant healing and osseointegration of pure titanium implants.
本研究探讨骨质疏松大鼠全身应用缩宫素(OT)对种植体骨整合的影响。
将20只大鼠随机分为对照组和实验组。首先,大鼠接受双侧卵巢切除术。12周后,建立骨质疏松模型。每只大鼠在股骨远端和中端干骺端植入一枚种植体。同时,进行全身给药,一组皮下注射OT(每天1mg·kg⁻¹),另一组注射安慰剂。治疗4周后,进行另一次手术,取出大鼠体内含有种植体的大腿骨,进行为期8周的观察。采用显微CT、组织学观察和推出试验评估骨整合情况。在大鼠接受大腿骨切除手术时,对两组大鼠进行另一次手术,取出胫骨干骺端进行组织学观察和显微CT检查。
与对照组相比,实验组胫骨样本的小梁骨密集,形成编织网状结构。实验组种植体周围的相对骨体积/组织体积、骨接触率和种植体最大推出力分别为0.35%±0.06%、67.25%±9.06%和(70.32±10.91)N,对照组相应值分别为0.11%±0.02%、43.25%±7.01%和(21.65±4.36)N,实验组与对照组相比显著增加(P<0.05)。
全身应用OT不仅可以拮抗骨质疏松的负面影响,还可以促进纯钛种植体的愈合和骨整合。